Terumo, Medis Team Up to Enhance Cardiovascular Care

Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), and cardiac imaging software company Medis Medical Imaging have begun a strategic partnership in the U.S.

The duo aims to boost cardiovascular care through using ePRISM, Terumo’s clinical decision support platform, and Medis’ Quantitative Flow Ratio (QFR) technology, a non-invasive software solution designed to assess angiography-derived coronary physiology. ePRISM and Medis QFR will be piloted at select clinical sites, leveraging real-time data from electronic health records (EHR) for prospective insights to enhance care.

The partnership will strive to enhance clinical decision support, streamline workflows, and improve outcomes by giving interventional cardiologists precise anatomical and physiological assessments of coronary artery disease (CAD).

Medis QFR uses an angiographic image-based approach, eliminating the need for a more invasive wire-based approach to assess coronary physiology. It can also evaluate multiple areas from the same images, in contrast to the wire-based approach which is vessel- and often lesion-specific.

FURTHER READING: GE HealthCare, Medis Medical Imaging Team Up for Non-Invasive Coronary Assessment

“This collaboration underscores Terumo’s commitment to building an innovative care operating system that not only improves clinical outcomes but also streamlines the entire care pathway,” said Ryan Graver, senior divisional VP of THO. “By utilizing our ePRISM platform alongside Medis’ QFR technology and TIS’ devices, we are equipping clinicians with a comprehensive suite that enhances procedural efficiency and patient outcomes. Together, we are redefining what’s possible in cardiovascular care.”

The FAVOR trials support Medis QFR

These EU trials, according to Medis, proved its QFR solution’s efficacy in practical use during and after an interventional procedure. The FAVOR III China trial showed a 34% decrease in major adverse cardiac events (MACE) in a one-year follow-up of patients treated with Medis QFR-guided versus standard angiography-guided procedures, and similar results were obtained after two years.

The FAVOR trials used first-gen QFR technology and demonstrated high accuracy compared to a pressure wire. This caused Medis QFR to be approved in Japan and included in the 2024 ESC guidelines for chronic coronary syndromes with a Class I recommendation.

The PIONEER IV trial, a 2,540-patient study, seeks to evaluate the superiority of the next-gen QFR technology for both pre- and post-procedure stenting recommendations. It will be integrated with THO’s ePRISM platform.

“At Medis Medical Imaging, we are thrilled to partner with Terumo Health Outcomes to push the boundaries of cardiovascular imaging and decision support,” said Maya Barley, CEO of Medis Medical Imaging. “This collaboration provides a comprehensive solution that enhances diagnostic accuracy and treatment planning. It highlights our dedication to improving patient care through innovation, working together with our worldwide network of partners.”